As per DelveInsight’s, the total diagnosed prevalent cases of Chronic Pain associated with Painful Diabetic Neuropathy in the 7MM is expected to increase at a CAGR of 0.64% during the study period 2018-30.
The Chronic Pain associated with the Painful Diabetic Neuropathy market is estimated to increase due to advancements in healthcare technology, high healthcare expenditure, and available reimbursement policies in developed countries. However, some of the factors such as lack of awareness among patients, availability of alternative treatments such as physiotherapy and pharmaceuticals, will hinder the growth of the Chronic Pain associated with the Painful Diabetic Neuropathy market in the coming years.
The key companies in the Chronic Pain associated with PDN market include Grünenthal Group, Daiichi Sankyo, Janssen Pharmaceutical, Pfizer, Eli Lilly, Shionogi, Ono Pharma, Fremslife, Helixmith, Aptinyx, Regenacy Pharmaceuticals, Novaremed AG, Nevro, Erchonia Corporation, Regenesis Biomedical, Abbott, Zygood, and many others. For more detailed information, visit: Chronic Pain Associated with Painful Diabetic Neuropathy Therapeutics Market